BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tak KY, Nam HC, Choi JY, Yoon SK, Kim CW, Kim HY, Lee SW, Lee HL, Chang UI, Song DS, Yang JM, Kwon JH, Yoo SH, Sung PS, Choi SW, Song MJ, Kim SH, Jang JW. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settings. Int J Cancer 2020;147:1970-8. [DOI: 10.1002/ijc.32964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
2 Chen S, Huang Y, Chen M, Hung Y, Lee R, Shao Y, Chao Y. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09173-4] [Reference Citation Analysis]
3 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]